Voyageur Secures $687k of Additional Capital From Warrant Exercises

Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) has bolstered its financial position with a significant capital raise, totaling $687,099, through the exercise of 5,725,829 share purchase warrants. This influx of capital, combined with the expiration of 11,419,935 unexercised warrants, has streamlined the company's capitalization table and positioned it for future growth and success.

The capital raise, which was completed on January 20, 2025, has provided Voyageur with added flexibility in achieving its goals to become a leader in the radiology drug market. The company's CEO, Brent Willis, expressed his gratitude for the strong support from existing investors, stating, "We sincerely appreciate the support our existing investors have placed in us. The warrant exercises will give Voyageur added flexibility in achieving its goals to become a leader in the radiology drug market."

Voyageur's strategic initiatives align with its long-term vision of becoming a vertically integrated leader in the radiology drug market. The company plans to utilize the newly acquired capital to fund several key projects, including:

1. FDA Applications for Barium Sulfate Contrast Media Product Line: Voyageur is preparing to submit FDA applications for its barium sulfate contrast media product line in 2025. This initiative aligns with the company's long-term vision of expanding its market reach and establishing a secure vertically integrated supply chain for radiology drugs in North America.
2. Strategic Partnerships: Voyageur is focused on fostering collaborations and strategic partnerships to drive growth and innovation. The company has already signed a letter of intent with a top-five contrast agent supplier to expand market reach and expedite vertical integration. This initiative aligns with the company's long-term vision of becoming a key player in the barium and iodine contrast markets by producing its own barium, iodine, and new endohedral fullerene drugs (C60).
3. Iodine Contrast Project: Voyageur is advancing its iodine contrast project in the U.S. with the goal of producing the lowest-cost iodine contrast drugs in the market. This initiative aligns with the company's long-term vision of addressing critical mineral supply constraints in North America and establishing the first secure, vertically integrated supply chain for radiology drugs in the region.
4. Fullerene-Based Contrast Drugs: Voyageur is developing fullerene-based contrast drugs in collaboration with Rain Cage Carbon. The company has successfully produced vanadium endohedral fullerene (V@C60) using the RC Carbon Capture Eden System technology. This initiative aligns with the company's long-term vision of pioneering new drug development programs and fostering collaborations to advance healthcare through cutting-edge science.



The expiration of unexercised warrants, totaling 11,419,935 warrants, has streamlined Voyageur's capitalization table by reducing the number of outstanding securities. This reduction in outstanding warrants simplifies the company's capital structure and makes it easier to manage and understand. Additionally, the expiration of these warrants reduces the potential dilution that could have occurred if they had been exercised, which is beneficial for existing shareholders.



In conclusion, Voyageur Pharmaceuticals Ltd. has strengthened its financial position and solidified its growth prospects through a significant capital raise and the streamlining of its capitalization table. With a clear roadmap for advancing its product pipeline and market position, Voyageur is well-positioned for sustained growth and success in 2025 and beyond.